Meta-analysis of the efficacy of Ospemifene in the treatment of post-menopausal vulvovaginal atrophy
Objective To evaluate the efficacy of Ospemifene in the treatment of postmenopausal vulvovaginal atrophy,in order to provide theoretical support for the clinical treatment of vulvovaginal atrophy.Methods Chinese and English literatures on the treatment of postmenopausal vulvovaginal atrophy were searched from CNKI,Wanfang Data,VIP,China Biomedical Database,PubMed,Embase,Cochrane Library,and Web of Science core collection databases.The search period was from the establishment of the database to April 2023.The literature quality evaluation was conducted using the Cochrane Handbook's randomized controlled trial bias risk assessment tool;Review Manager 5.3 was used for meta-analysis of the included literature.Results Seven randomized controlled trials were included,including 2 649 patients,including 1 624 cases in Ospemifene group and 1 025 cases in placebo group.There was no significant difference in endometrial increment between two groups(OR=3.74,95％CI:0.79,17.75,P=0.10).Compared with placebo group,the incidence of endometrial thickening increased(OR=1.22,95％CI:1.01,1.47,P=0.03)and vaginal pH decreased(SMD=-1.22,95％CI:-1.45,-0.98,P＜0.000 01),vaginal dryness relieved(SMD=-0.38,95％CI:-0.55,-0.21,P＜0.000 1),and the incidence of adverse reactions increased(OR=1.49,95％CI:1.28,1.74,P＜0.000 01).Conclusion Ospemifene can thicken the endometrium,reduce vaginal pH,and relieve vaginal dryness,although it increases the incidence of adverse reactions to a certain extent,it is still a reliable treatment for vulvovaginal atrophy.
万方数据
维普
